OBJECTIVE: Occasionally, a favorable clinical diseasespecific outcome does not reflect into improved generic health-related quality of life (HRQoL) in patients with idiopathic normal-pressure hydrocephalus (iNPH) at 1 year after the installation of a cerebrospinal fluid shunt. Our aim was to identify factors causing this discrepancy.
-METHODS: The 1-year HRQoL outcomes of 141 patients with iNPH were evaluated with the generic 15D instrument, in which the minimum clinically important change/difference on the 0e1 scale has been estimated to be AE0.015. A 12-point iNPH grading scale (iNPHGS) was used as a clinical disease-specific outcome measure, in which a 1-point decrease is considered to be clinically important. We identified 29 (21%) patients with iNPH from our prospective study whose HRQoL deteriorated or remained the same despite of a favorable iNPHGS outcome. We analyzed this discrepancy using patients' clinical variables and characteristics.
-RESULTS: Multivariate binary logistic regression analysis indicated that a greater (worse) iNPHGS score at baseline (adjusted odds ratio [OR], 1.7; 95% confidence interval [CI] 1.3e2.3; P < 0.001), comorbid chronic pulmonary disease (40% vs. 20%; adjusted OR 17.8; 95% CI 3.6e89.9; P < 0.001), and any comorbid nonmetastatic tumor (62% vs. 17%; adjusted OR 11.5; 95% CI 1.5e85.3; P [ 0.017) predicted discrepancy between iNPHGS and 15D outcomes. INTRODUCTION T here is an occasional discrepancy between the patientreported (PRO) and clinician-reported (ClinRO) outcomes, but the extent of this phenomenon, its etiology, and how it behaves in different patient populations are largely unknown. 1 The few studies conducted on this topic suggest that physicians tend to estimate the efficacy of treatment better than Key words -15D -Comorbidity -Discrepancy -Health-Related Quality of Life -iNPHGS -Normal-pressure hydrocephalus -Patient-reported outcome patients. [1] [2] [3] This might be due to the information asymmetries between the physician and the patient, 1,2 unmet expectations, 3 or the "response shift" phenomenon. 4 In contrast, PROs, such as Health-Related Quality of Life (HRQoL), may appreciate aspects not captured by ClinROs. [5] [6] [7] [8] [9] Recently, we published a prospective 1-year follow-up study of HRQoL outcome in patients with idiopathic normal-pressure hydrocephalus (iNPH), 9 a progressing condition of elderly patients that characteristically impairs their gait, cognition, and urinary continence. [10] [11] [12] The so-far unknown origin has been contemplated to cause various abnormalities in the cerebrospinal fluid (CSF) physiology and hydrodynamics, which ultimately lead to the symptoms and signs observed in patients with iNPH. 11, 12 iNPH itself is a diagnostic challenge, where patients are by the current guidelines classified by the increasing probability to have the condition, rather than having or not having the illness. 11, 12 The only available treatment, CSF shunt surgery, has been reported to relieve some of the symptoms in a majority of patients with iNPH. 13 Another unresolved question is the use of PROs in patients with cognitive impairment, who are suspected to lack insight for selfevaluation as the illness progresses. 7, 8 Reports concerning the required cognitive function for PROs are rare, and it has been speculated whether participants should be excluded from PROs if they reach certain stage of dementia. 7, 8 Despite of 2 decades of research, investigators have found very little common ground in choosing a HRQoL instrument for patients with dementia, determining the optimal way of administrating it, and deciding what dimensions and qualities it should or should not have. 7, 8, 14, 15 Only little is known about HRQoL in iNPH, 9 and there are no guidelines for the measurement of HRQoL in iNPH.
In our study, 9 a PRO (15D HRQoL instrument) and a ClinRO (iNPH Grading Scale, iNPHGS) seemed to match, as the favorable outcome rate using both instruments was alike (44% vs. 48%). When investigated further, a lack of strong correlation between the changes in the 15D and the iNPHGS scores raised the question of possible discrepancy between the 2 ( Table 1 and Supplementary Figure 1A This led to the current study aiming to determine 1) how common is the discrepancy between the PRO and the ClinRO in iNPH patients measured by HRQoL (15D) and iNPHGS, respectively; 2) do patients with discrepancy differ from the rest of the study population; and 3) are there explanatory factors for the discrepancy, such as cognition impairment, depressive symptoms, or neurodegenerative comorbidity?
MATERIALS AND METHODS
The permission for the research was received from the Research Ethics Board of the Kuopio University Hospital (KUH), a hospital that geographically serves neurosurgery to the Eastern Finnish population of about 900,000 inhabitants. Patients suspected of having iNPH in this epidemiologic area were examined primarily by a neurologist and referred for further neurosurgical investigations if they displayed 1e3 symptoms possibly related to NPH (impaired cognition, impaired gait, or urinary continence) accompanied with enlarged brain ventricles disproportionate to the size of the sulci of cerebral convexities (Evan's index >0.30) on computed tomography or magnetic resonance imaging. 11 Between April 2009 and February 2015, data were collected in the Neurosurgery Department of KUH from 245 consecutive patients with suspected iNPH who provided written informed consent (Figure 1 ). 17 The HRQoL questionnaires were completed by an interviewing nurse or by participants themselves and stored in the NPH Registry of KUH (www.uef.fi/nph). As 56 patients were excluded from further research because of insufficient data, not having iNPH, or not having CSF shunt (Figure 1) , the primary prospective 1-year follow-up study was performed with 189 participants, of whom 145 (77%) completed the HRQoL follow-up ( Figure 1 ). 9 Regarding this study population, the selection procedure for the CSF shunts has been described in detail previously. 9 Information on the CSF shunt types and prognostic tests used can be found in Tables 1 and 2.
As both 1-year iNPHGS and 15D scores were essential for analyzing the discrepancy between the 2, 4 patients missing a 1-year iNPHGS score were excluded ( Figure 1) . As a result, 141 participants were included in the analysis (Figure 1 ). Participants were classified to have a negative discrepancy if they did not have a clinically important improvement in HRQoL despite of having at least a minimum clinically important improvement in the iNPHGS score 1-year after the shunting (Supplementary Figure 1 , 16 Tables 1 and 2) and a positive discrepancy if they had experienced at least a minimum clinically important improvement in the 15D score but the iNPHGS score did not show a clinically important improvement ( Table 1) .
Evaluation of INPH Symptoms and the Clinical Outcome Measure
To classify the triad of symptoms featuring iNPH (cognitive impairment, impaired gait, and urinary disturbance) we used a modified Finnish version of the 12-point iNPH Grading Scale (iNPHGS), 18 which is a clinician-rated scale to separately assess the severity of each symptom with scoring based on observations by the physician and interviews with the patients or their caregivers. 18 Subscores for each dimension range from 0 to 4, with greater scores representing worse symptoms. 18 A minimum clinically important decrease in the iNPHGS score has been estimated to be 1 point. 19 The HRQOL Instrument The generic HRQoL instrument used in our study, the 15D, contains 15 dimensions of health: mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, depression, distress, vitality, and sexual activity. 17 Each dimension has 5 ordinal levels; one must choose the most suitable level portraying one's state of health at the moment. 17 The 15D instrument produces dimension level values and a single index score (15D score) by using set of population-based preference weights acquired from the Finnish population. 17 The 15D score that combines all the dimensions to one index on a 0 to 1 scale, with 0 referring to being dead and 1 being at full health. 17 The minimum clinically important change/ difference in the 15D score has been estimated to be !0.015. 16 
Characteristics and Comorbidities
Comorbidities and attributes were recorded from all the patients undergoing surgery in the KUH. The Charlson Age Comorbidity Index (CACI) was used to estimate the burden caused by coexisting conditions ( Table 3) . 20 CACI combines 19 medical conditions so that each comorbidity corresponds to a weighted number, with a greater number representing greater burden. 20 By adding up all the numbers, and 1 point for each decade over the age of 40 years, a final CACI score can be calculated. 20 
Education
As the primary education in Finland lasts for 9 years, patients were dichotomized according to the educational years achieved in life-time: those with 9 years or less of education and to those with more. 
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Biopsy Procedure and Immunohistochemistry Preceding the insertion of the CSF shunt's ventricular catheter (approximately 3 cm from the midline and near to the coronal suture of the scalp), biopsy forceps or needle were used to retrieve 1e3 cylindrical cortical brain biopsies of 3e7 mm in length and 2e5 mm in diameter. The details of the biopsy and its immunohistochemistry analysis have been described previously. 21, 22 From all samples, the cellular or neuritic immunoreactivity for amyloid-beta (Abeta) and hyperphosphorylated tau (HPtau) were evaluated by light microscopy and were graded as present or absent by a neuropathologist ( Tables 1 and 2) . 22 Patients were then further divided by the presence of pathology of any kind, the Abeta or HPtau observed in the frontal cortical biopsy.
Cognitive Evaluation
Mini-Mental State Examination (MMSE) was used to evaluate patients' cognitive function. 23 MMSE ranges from 0 to 30, with greater scores representing better cognitive function. 23 The preoperative MMSE score was converted to dementia staging in accordance with the Clinical Dementia Rating ( Table 2 ). 24
Assessment of Depressive Symptoms
Depressive symptoms were assessed with the self-administered 21-item Finnish version of the Beck Depression Inventory (BDI) ( Table 3) . 25 Each item includes 4 statements that have a numerical value from 0 to 3. The questionnaire's total score ranges from 0 to 63, with greater scores indicating more severe depressive symptoms. 25 The gathering of BDI from all consecutive patients started first in January 2011, consequently, BDI data are missing from some patients. The reason to focus on negative discrepancy was made on clinical basis, as such a discrepancy can be seen as an unpredicted and unfavorable phenomenon unlike the positive discrepancy. To predict the negative discrepancy, uni-and multivariate binary logistic regression analyses were performed with the enter method ( Table 4 and Supplementary Table 1 ). 26 The potential effect of missing data on the regression results was estimated with multiple imputation by chained equations ( Table 4 and Supplementary Table 2 ). 27 Variables were included in the multivariate model if they reached a moderate tendency toward significance in univariate analyses (P 0.25) ( Table 4) , 26 and those excluded were recorded (Supplementary Table 1 ). The odds ratios (ORs) were calculated with 95% confidence intervals (CIs). All tests for significance were 2-sided, with probabilities of <0.05 accepted as statistically significant.
RESULTS
A total of 52 patients (37%) had inconsistency between their 1-year 15D and iNPHGS scores ( Patients with a negative discrepancy had greater comorbidity burden (ManneWhitney U-test, P ¼ 0.016), body mass index (ManneWhitney U test, P ¼ 0.018), and iNPHGS (Manne Whitney U-test, P < 0.001) scores and had greater frequency of subjective hearing loss (Fisher exact test, P ¼ 0.029, 41% vs. 21%) than those without a negative discrepancy ( Table 2) . Patients with a negative discrepancy also had a greater prevalence of comorbid chronic pulmonary disease (Fisher exact test, P ¼ 0.001, 28% vs. 5%) and history of myocardial infarctions (Fisher exact test, P ¼ 0.034, 41% vs. 21%) than those without discrepancy ( Table 3) .
A secondary statistical analysis was performed for patients with positive discrepancy ( Supplementary Table 3 ). Patients with a positive discrepancy had lower iNPHGS score at baseline (ManneWhitney U test, P < 0.001) than those without a positive discrepancy ( Supplementary Table 3 ).
Regression Analysis
Multivariate binary logistic regression analysis was performed with negative discrepancy (yes ¼ 1, no ¼ 0) as the dependent variable ( Table 4) . According to the model, baseline INPHGS score (adjusted OR 1.7; 95% CI 1.3e2.3; P < 0.001), comorbid chronic pulmonary disease (40% vs. 20%; absolute risk difference, 20%; adjusted OR 17.9; 95% CI 3.6e89.9; P < 0.001), and comorbid nonmetastatic tumor (62% vs. 17%; absolute risk difference, 42%; adjusted OR 11.5; 95% CI 1.5e85.3; P ¼ 0.017) predicted negative discrepancy between INPHGS and 15D outcomes 1 year after the shunting. The model had good fit as demonstrated by the HosmereLemeshow test ( Table 4) , and 86% of the patients were classified correctly. The highest variance inflation factor was 1.2 (baseline iNPHGS score) and the lowest tolerance was 0.8 (baseline iNPHGS score), suggesting that multicollinearity did not have a significant effect on the model. Multiple imputation by chained equations confirmed that analysis results were robust to the missing data.
DISCUSSION

Limitations and Generalizability
There are no universally agreed diagnostic criteria for iNPH. 11, 12 Proxy-rated HRQoL data were not gathered. The study was restricted to one geographical area, and the results can be only applied to a similar population. A generic HRQoL measure with potentially lower sensitivity to detect a change in patients with cognitive impairment was used instead of a disease-specific HRQoL measure. 7, 8 The study lacks a more detailed neuropsychological test and validated evaluation of daily functions. There is a possibility of small variation between the physicians when it comes to the usage of a clinician-rated iNPHGS scale. The significance of different radiological variables used in the diagnostics of iNPH was not evaluated.
Interpretation
In our study, a participant with poor starting point (High iNPHGS score) was more likely to experience unimproved generic HRQoL while having a favorable clinical disease-specific outcome. It could be that in these cases the participant's wish to become fully functioning after the operation is unmet, which may explain the unimproved HRQoL. 3 As old patients affected by a condition with poor prognosis are at an increased risk for misunderstanding the goals of the treatment/study, 28 one might justifiably say that in these terms patients with cognitive impairment are very vulnerable. An unfortunate complication, such as hearing impairment after CSF shunting, may cause unimproved HRQoL despite of otherwise-improved functionality and thus negate the favorable outcome. 9 It could be argued that similarly patients with co-existing chronic pulmonary disorder or any nonmetastatic tumors are more likely to find themselves where they left in terms of HRQoL, as the CSF shunting does not affect the severe generic HRQoL impairment caused by these comorbidities. 29 These findings are in accordance with the conceptual model of HRQoL presented Wilson and Cleary, 30 where not only the symptom status and disease process but the characteristics of the individual and the environment influence the perception of general health and HRQoL. 30 Relkin et al. 2005, 12 from which the physiological criterion (IV) for probable iNPH was not included, as CSF opening pressure was measured only from patients going through infusion tests in our study population. **Diagnostic criteria by Relkin et al. 2005. between the PRO and PROM rationalizes, in its very essence, the use of both measurements and elucidates the limitations if used alone. [5] [6] [7] [8] [9] 30 An exciting finding was that neither the absence of Abeta and HPtau pathology in the frontal cortical biopsy (indicating the absence of comorbid Alzheimer disease pathology) nor a better cognitive function decreased the likelihood of discrepancy. However, our results should be interpreted cautiously, as generic utility measurements, such as the 15D instrument, might have limited sensitivity to detect health status changes in persons with cognitive impairment. 7, 8 Although many patients lack full insight already early on in the cognitive impairment, self-rated HRQoL has unique value, but should always be accompanied with other outcome measures. 7, 8 Although some self-rated generic HRQoL instruments (SF-12, EQ-5D) have been reported to be able to detect change in the health status of patients with iNPH, 5,31 more 
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the iNPHGS score remained the same or increased (got worse) ( Table 1) . These participants had less severe iNPHGS symptoms at baseline but were otherwise very similar to the rest of the study population ( Supplementary Table 3 ), suggesting that there might be psychological or nonmedical factors influencing the HRQoL outcome even though these attributes could not be captured by our study. 4, 30 Similarly, it has been hypothesized, that in these patients with iNPH, HRQoL captures subtle improvements caused by CSF shunting and that are not portrayed by objective measurements. 5 In future studies, the potential effect of CSF shunt valve adjustments to ClinRO and PRO outcomes would be undoubtedly worthy of further research.
In conclusion, frail patients suffering from certain pre-existing comorbidities may not experience improvement in generic HRQoL despite of a favorable clinical disease-specific response to CSF shunt surgery. The absence of Abeta and HPtau pathology in the frontal cortical biopsy, or a better cognitive function, do not protect from the negative discrepancy. Acknowledging the comorbidity burden of the patient may help clinicians and the patients to better understand the conflict between PRO and ClinRO.
